Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
BMS Expands Dealings With Otsuka
by Alexander H. Tullo
April 13, 2009
| A version of this story appeared in
Volume 87, Issue 15
Bristol-Myers Squibb and Japan's Otsuka Pharmaceutical have expanded an existing development and commercialization deal and set up a new one in oncology. The two companies have extended their deal for the antipsychosis drug Abilify by three years to 2015. They will also jointly develop and sell the BMS oncology products Sprycel and Ixempra. BMS will pay Otsuka $400 million in cash up front and a share of product sales, and Otsuka will contribute to commercialization expenses.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter